DMARDs are usually considered when a child has moderate to severe symptoms that do not respond to nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Early initiation of DMARDs is recommended to prevent long-term joint damage and improve overall prognosis.
